{
  "guideline": {
    "id": "PA166104776",
    "name": "Annotation of FDA Label for warfarin and CYP2C9, PROC, PROS1, VKORC1",
    "source": "FDA",
    "version": 35,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166104776",
    "relatedChemicals": [
      {
        "id": "PA451906",
        "name": "warfarin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      },
      {
        "id": "PA33799",
        "name": "protein C, inactivator of coagulation factors Va and VIIIa",
        "symbol": "PROC"
      },
      {
        "id": "PA33809",
        "name": "protein S",
        "symbol": "PROS1"
      },
      {
        "id": "PA133787052",
        "name": "vitamin K epoxide reductase complex subunit 1",
        "symbol": "VKORC1"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166324232",
      "name": "Recommendation Annotation PA166324232",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337691,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*2/*3, VKORC1 AA (rs9923231 TT), the range of expected maintenance daily dose is 0.5-2 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*2": 1.0,
          "*3": 1.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324243",
      "name": "Recommendation Annotation PA166324243",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337702,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*1/*1, VKORC1 AG (rs9923231TC), the range of expected maintenance daily dose is 5-7 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 2.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 1.0,
          "rs9923231 reference (C)": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324230",
      "name": "Recommendation Annotation PA166324230",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337689,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*2/*2, VKORC1 AG (rs9923231 TC), the range of expected maintenance daily dose is 3-4 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*2": 2.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 1.0,
          "rs9923231 reference (C)": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324236",
      "name": "Recommendation Annotation PA166324236",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337695,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*1/*1, VKORC1 GG (rs9923231CC), the range of expected maintenance daily dose is 5-7 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 2.0
        },
        "VKORC1": {
          "rs9923231 reference (C)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324234",
      "name": "Recommendation Annotation PA166324234",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337693,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*2/*3, VKORC1 GG (rs9923231CC), the range of expected maintenance daily dose is 3-4 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*2": 1.0,
          "*3": 1.0
        },
        "VKORC1": {
          "rs9923231 reference (C)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324261",
      "name": "Recommendation Annotation PA166324261",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337740,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*1/*3, VKORC1 AA (rs9923231 TT), the range of expected maintenance daily dose is 0.5-2 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*3": 1.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324228",
      "name": "Recommendation Annotation PA166324228",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337687,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*3/*3, VKORC1 AA (rs9923231 TT), the range of expected maintenance daily dose is 0.5-2 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*3": 2.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324241",
      "name": "Recommendation Annotation PA166324241",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337700,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*2/*3, VKORC1 AG (rs9923231 TC), the range of expected maintenance daily dose is 0.5-2 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*3": 2.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 1.0,
          "rs9923231 reference (C)": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324265",
      "name": "Recommendation Annotation PA166324265",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337744,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*1/*2, VKORC1 AG (rs9923231TC), the range of expected maintenance daily dose is 3-4 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*2": 1.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 1.0,
          "rs9923231 reference (C)": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324263",
      "name": "Recommendation Annotation PA166324263",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337742,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*1/*3, VKORC1 GG (rs9923231CC), the range of expected maintenance daily dose is 3-4 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*3": 1.0
        },
        "VKORC1": {
          "rs9923231 reference (C)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324233",
      "name": "Recommendation Annotation PA166324233",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337692,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*2/*3, VKORC1 AG (rs9923231 TC), the range of expected maintenance daily dose is 0.5-2 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*2": 1.0,
          "*3": 1.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 1.0,
          "rs9923231 reference (C)": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324231",
      "name": "Recommendation Annotation PA166324231",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337690,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*2/*2, VKORC1 GG (rs9923231CC), the range of expected maintenance daily dose is 3-4 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*2": 2.0
        },
        "VKORC1": {
          "rs9923231 reference (C)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324242",
      "name": "Recommendation Annotation PA166324242",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337701,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*2/*2, VKORC1 AA (rs9923231 TT), the range of expected maintenance daily dose is 0.5-2 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*2": 2.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324266",
      "name": "Recommendation Annotation PA166324266",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337745,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*1/*2, VKORC1 GG (rs9923231CC), the range of expected maintenance daily dose is 5-7 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*2": 1.0
        },
        "VKORC1": {
          "rs9923231 reference (C)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324235",
      "name": "Recommendation Annotation PA166324235",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337694,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*1/*1, VKORC1 AA (rs9923231 TT), the range of expected maintenance daily dose is 3-4 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 2.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324229",
      "name": "Recommendation Annotation PA166324229",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337688,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*3/*3, VKORC1 GG (rs9923231CC), the range of expected maintenance daily dose is 0.5-2 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*3": 2.0
        },
        "VKORC1": {
          "rs9923231 reference (C)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324264",
      "name": "Recommendation Annotation PA166324264",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337743,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*1/*2, VKORC1 AA (rs9923231\nTT), the range of expected maintenance daily dose is 3-4 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*2": 1.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166324262",
      "name": "Recommendation Annotation PA166324262",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451906",
          "name": "warfarin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337741,
        "html": "<p>Table 1 in the drug label provides ranges of expected maintenance daily doses of warfarin (COUMADIN) based on CYP2C9*2, CYP2C9*3 and VKORC1−1639G&gt;A (rs9923231) genotypes. For CYP2C9*1/*3, VKORC1 AG (rs9923231 TC), the range of expected maintenance daily dose is 3-4 mg.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*3": 1.0
        },
        "VKORC1": {
          "rs9923231 variant (T)": 1.0,
          "rs9923231 reference (C)": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product COUMADIN (warfarin sodium), NDA009218, Bristol-Myers Squibb Pharma Company",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009218"
    }
  ],
  "version": "2024-02-29-20-19"
}